HCM
CRDF icon

Highlander Capital Management’s Cardiff Oncology CRDF Stock Holding History

Highlander Capital Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-28
Closed -$4K – 765
2016
Q4 		$4K Sell
28
-180
-87% -$42K ﹤0.01% 694
2016
Q3 		$67K Buy
208
+97
+87% +$35.4K 0.06% 299
2016
Q2 		$36K Sell
111
-97
-47% -$33.4K 0.03% 418
2016
Q1 		$70K Sell
208
-161
-44% -$54.8K 0.07% 290
2015
Q4 		$144K Hold
369
– – 0.13% 183
2015
Q3 		$151K Buy
369
+258
+232% +$135K 0.14% 180
2015
Q2 		$81K Buy
+111
New +$78.7K 0.07% 286

Other funds holding CRDF

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EP
Elkhorn Partners Omaha, Nebraska $117M AUM 28.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Highlander Capital Management's CRDF Position: Q1 2017 in Review

Highlander Capital Management sold out of Cardiff Oncology (CRDF) in Q1 2017, closing a stake of 28 shares — an estimated $4K sold.

Highlander Capital Management first reported a position in CRDF in Q2 2015 and held it in 7 quarters. The position peaked at $151K in Q3 2015. 62 funds tracked by Wall St. Rank hold CRDF as of Q1 2017.

  • Highlander Capital Management reported no remaining Cardiff Oncology position as of Q1 2017 after selling out during the quarter.
  • Highlander Capital Management sold 28 Cardiff Oncology shares in Q1 2017, an estimated $4K.
  • Highlander Capital Management first reported a position in Cardiff Oncology in Q2 2015 and held it in 7 quarters.
  • Highlander Capital Management's Cardiff Oncology position peaked at $151K in Q3 2015.
  • 62 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2017.

Based on Highlander Capital Management's 13F filing for Q1 2017, filed 15 May 2017.